Skip to main content
. 2022 Jun 11;119:106822. doi: 10.1016/j.cct.2022.106822

Fig. 1.

Fig. 1

Epidemiology of Monoclonal Antibody Infusions. Panel A shows the number of mAb-infused patients among the EHR screen eligible. Panel B shows the proportion of mAb-infused patients among EHR screen eligible by White or Black race. Hispanic ethnicity, Other, and Unknown race are not shown due to small sample sizes. Panel C shows the number of mAb infusions per 1000 cases prior to March 10, 2021. Panel D shows the number of mAb infusions per 1000 cases after March 10, 2021. Zip codes with <10 COVID-19 cases or those outside of Pennsylvania are not shown.

Interpretive example: Prior to the trial (panel A), mAb infusion was low. In panel B, the proportion of White and Black race infused among EHR-screen eligible patients increased. In the UPMC catchment in Pennsylvania, mAb infusions also increased in amount (darker, panel C, D) and in geographic distribution (more zip code areas colored) during OPTIMISE-C19.